在帕金森病中治疗情绪功能障碍的psilocybin治疗:一个开放标签的试点试验
Ellen R Bradley1,2, Kimberly Sakai3, Gisele Fernandes-Osterhold3,4
1Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. ellen.bradley@ucsf.edu.
概括
西治疗对帕金森病 (PD) 患有抑郁症和焦虑症的患者显示出前景. 这项试点研究发现它是安全有效的,可以改善情绪,运动和认知症状,而不会恶化PD.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 临床药理学 临床药理学
背景情况:
- 情绪功能障碍,包括抑郁和焦虑,在帕金森病 (PD) 中很常见,并影响生活质量.
- 目前用于PD情绪障碍的治疗方法通常有效性有限,并且可能产生副作用.
- 需要新的治疗干预措施来管理PD等神经退行性疾病中的情绪症状.
研究的目的:
- 评估在患有轻度至中度帕金森病 (PD) 且患有抑郁症和/或焦虑症的个体中以psilocybin辅助治疗的可行性和安全性.
- 评估psilocybin治疗对PD非运动和运动症状的影响.
- 为了检查PD患者在psilocybin治疗后认知功能和情绪评级的变化.
主要方法:
- 一项开放式试点研究 (NCT04932434) 涉及12名患有PD和情绪症状的参与者.
- 参与者接受了 псилоцибин治疗,包括10毫克剂量,其次是25毫克剂量,与心理治疗相结合.
- 使用诸如运动障碍学会统一帕金森病评分表 (MDS-UPDRS),蒙哥马利-阿斯伯格抑郁评分表 (MADRS) 和汉密尔顿焦虑评分表 (HAM-A) 等措施来评估安全性和有效性.
主要成果:
- 发现在psilocybin治疗是可行的和安全的,没有严重的不良事件或精神病恶化的报道.
- 参与者在非运动 (MDS-UPDRS Part I) 和运动症状 (MDS-UPDRS Part II和III) 中显著改善.
- 观察到临床上有意义的抑郁症 (MADRS) 和焦虑症 (HAM-A) 评分的降低,以及特定认知领域的改善,持续治疗后长达三个月.
结论:
- 松素辅助治疗似乎是对患有帕金森病 (PD) 的个人经历抑郁和焦虑的安全和潜在有效的干预措施.
- 这项研究提供了初步证据,证明psilocybin在改善PD患者的情绪,运动功能和认知方面的好处.
- 需要进行进一步的研究,包括随机对照试验,以证实这些发现,并探索psilocybin在神经退行性疾病中的治疗潜力.
相关概念视频
Parkinson's Disease: Treatment
161
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161
Parkinson's Disease: Overview
342
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
342
Mania and Antimanic Drugs: Overview
106
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
106
EPS and iPS Cells in Disease Research
2.7K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.7K
Antidepressant Drugs: MAOIs and Other Agents
170
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
170


